Etat des connaissances en 2018 sur les anticorps anti-PCSK9 [Current update on PCKS9 inhibitors]

Détails

ID Serval
serval:BIB_E00ED676BFC5
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Etat des connaissances en 2018 sur les anticorps anti-PCSK9 [Current update on PCKS9 inhibitors]
Périodique
Revue medicale suisse
Auteur(s)
Gencer B., Nanchen D., Collet T.H., Rodondi N., Mach F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
28/02/2018
Peer-reviewed
Oui
Volume
14
Numéro
596
Pages
482-486
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (mAb) are new therapeutic agents to lower efficiently LDL-cholesterol levels. New data from large clinical trials suggest that the addition of PCSK9 mAb to statins can reduce the incidence of major adverse cardiovascular events in very high risk patients. Alirocumab and evolocumab are two agents available in Switzerland with specific limitations for reimbursement. PCSK9 mAb should be considered in patients with clinical atherosclerotic cardiovascular disease (ASCVD), as well as in patients with familial hypercholesterolemia without ASCVD who have substantially high LDL-cholesterol levels despite the use of statin at maximally tolerated dose with or without ezetimibe, or intolerance to appropriate doses of several statins.
Mots-clé
Antibodies, Monoclonal/therapeutic use, Anticholesteremic Agents, Cholesterol, LDL, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hypercholesterolemia/drug therapy, Proprotein Convertase 9/antagonists & inhibitors, Switzerland
Pubmed
Création de la notice
03/03/2018 13:58
Dernière modification de la notice
20/08/2019 17:04
Données d'usage